Innovative technologies

Pfizer Inc and its German partner BioNTech on Monday sought the U.S. Food and Drug Administration's authorization for an Omicron-tailored COVID-19 vaccine booster for children aged 5 through 11 years.

The application comes just days after Moderna also applied for FDA authorization of its own Omicron-targeting shot in adolescents aged 12 to 17 years and children aged six to 11.

Business morale in Germany this month slumped to its lowest level since the early days of the pandemic, according to a leading survey of companies in Europe's largest economy.

U.S. stocks are seen opening lower Monday, continuing the previous week’s rout with investors concerned about future growth after the Federal Reserve ramped up its fight against inflation.